Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1631672 | 0.86 | HCRTR2 (0.58) | HCRTR2KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL1630720 | 0.84 | HCRTR2 (0.58) | HCRTR2KEAP1NFE2L2MEN1KMT2A | |
| Acetic Acid SCHEMBL1920216 | 0.82 | HCRTR2 (0.56) | HCRTR2KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL1629459 | 0.81 | TSHR (0.63) | KEAP1NFE2L2SMN1; SMN2TSHRMAPT | |
| SCHEMBL1630305 | 0.78 | KEAP1 (0.71) | KEAP1NFE2L2MEN1KMT2AL3MBTL1 | |
| SCHEMBL1630563 | 0.78 | KEAP1 (0.62) | KEAP1NFE2L2KMT2AL3MBTL1TSHR | |
| SCHEMBL1629105 | 0.77 | HSD11B1 (0.45) | HCRTR2KCNA5MEN1KMT2ALMNA | |
| SCHEMBL1629149 | 0.76 | HCRTR2 (0.58) | HCRTR2KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL1630148 | 0.74 | HCRTR2 (0.61) | HCRTR2KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL1631802 | 0.73 | KCNA5 (0.43) | HCRTR2KCNA5MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| EP-2245006-B1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-01 | — | — | EP | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932269-B2 | Sulfonamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-04-26 | — | — | US | disclosed |
| WO-2009092642-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-30 | — | — | WO | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186920-A1 | SULFONAMIDES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | HCRTR2 1/4885KEAP1 1802/4885NFE2L2 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.